ASS1 and metastatic melanoma: Thus, we conducted this pharmacodynamic Phase 1 trial of ADI-PEG20 and cisplatin in patients with pretreated metastatic melanoma or other advanced ASS1-deficient malignancies and the main aims were to evaluate the safety, tolerability and efficacy of this combination treatment.